Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Drug Management Programs Formalize Pharmacist Role As Provider

This article was originally published in The Pink Sheet Daily

Executive Summary

Medication therapy management programs created by the Medicare drug benefit are “the single greatest opportunity for pharmacy in over 30 years,” Kerr Drugs exec tells NACDS conference. Potential fees from such programs are a significant compensation opportunity for pharmacies, Longs Drugs VP says.

You may also be interested in...



Pharmacists Must Create Patient Demand for Medication Therapy Management

Patients must be shown the value of medication therapy management, Walgreens exec Daniel Luce says. CMS warns pharmacists to be conservative in predicting compensation available from the Medicare drug benefit’s medication therapy management component.

Pharmacists Must Create Patient Demand for Medication Therapy Management

Patients must be shown the value of medication therapy management, Walgreens exec Daniel Luce says. CMS warns pharmacists to be conservative in predicting compensation available from the Medicare drug benefit’s medication therapy management component.

Medication Therapy Management Model Issued By NACDS, APhA

The framework issued by the National Association of Chain Drug Stores and American Pharmacists Association includes five “core elements” for pharmacists developing MTM services under Part D.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel